← back to search

Alessandro Pastore

Novartis (United States) · US
Area of research
Molecular Biology · Cancer Research
Research interest
Research interests include Cancer Genomics and Diagnostics, Lymphoma Diagnosis and Treatment, Nuclear Structure and Function, and RNA Research and Splicing.
h-index
39
citations
9,268
works
109
NIH funding
primary concept
Medicine
email

Recent publications

Supplementary Table Captions from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Table S3 from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Table S1 from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Data from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Table S6 from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Table S2 from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Table S2 from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Supplementary Methods from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Table S1 from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Table S5 from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Supplementary Figures from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Supplementary Methods from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Table S4 from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Table S5 from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Table S3 from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Table S4 from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Supplementary Table Captions from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Data from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Supplementary Figures from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Table S6 from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023cited by 0position: contributordoi
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.
2022cited by 204position: contributordoi
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Nature Biotechnology 2021cited by 266position: middledoi
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer
Cancer Cell 2020cited by 156position: middledoi
Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma
Cell Reports 2020cited by 75position: middledoi
Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia
Cancer Cell 2019cited by 369position: middledoi
Lactose drives <i>Enterococcus</i> expansion to promote graft-versus-host disease
Science 2019cited by 366position: middledoi
Somatic mutations and cell identity linked by Genotyping of Transcriptomes
Nature 2019cited by 330position: middledoi
Lactose drives <i>Enterococcus</i> expansion to promote graft-versus-host disease.
2019cited by 303position: contributordoi
Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia
Nature 2019cited by 267position: middledoi
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.
2019cited by 178position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 25 papers (2019–2023)Justin Taylor · University of Miami22 papers (2019–2023)Akihide Yoshimi · Kitasato University22 papers (2019–2023)Michael G. Kharas · Weill Cornell Medicine21 papers (2019–2023) · 21 papers (2019–2023)Gorka Prieto · University of the Basque Country21 papers (2019–2023)Florisela Herrejon Chavez · Memorial Sloan Kettering Cancer Center21 papers (2019–2023)Alexander V. Penson · Memorial Sloan Kettering Cancer Center21 papers (2019–2023) · 21 papers (2019–2023)Omar Abdel‐Wahab · Presbyterian Hospital5 papers (2017–2019)Wolfgang Hiddemann · Deutsche Forschungsgemeinschaft5 papers (2014–2019)Sydney X. Lu · Stanford University4 papers (2019–2019)Martin Dreyling · Hospital Universitario 12 De Octubre4 papers (2017–2019)Oliver Weigert · München Klinik4 papers (2017–2019)Randy D. Gascoyne · BC Cancer Agency3 papers (2017–2018)Eva Hoster · Zimmer Biomet (Netherlands)3 papers (2018–2019)Robert Kridel · Princess Margaret Cancer Centre3 papers (2017–2018)Johannes C. Hellmuth · LMU Klinikum3 papers (2017–2018)Stefan Alig · Palo Alto University3 papers (2018–2019)Sarah Haebe · LMU Klinikum2 papers (2018–2019)